phio pharmaceuticals corp., a biotechnology company, develops immuno-oncology therapeutics in the united states. it offers intasyl therapeutic platform focuses on silencing tumor-induced suppression of the immune system. the company develops ph-762 which targets the checkpoint protein pd-1 on immune cells for used in adoptive cell transfer (act); ph-804 that targets the suppressive immune receptor tigit, which is a checkpoint protein present on t cells and natural killer cells for used in act; and ph-790 which targets pd-l1 protein that keeps immune cells from attacking nonharmful cells in the body. it has collaborations with the gustave roussy and medigene ag, as well as with helmholtz zentrum mã¼nchen. the company was formerly known as rxi pharmaceuticals corporation and changed its name to phio pharmaceuticals corp. in november 2018. phio pharmaceuticals corp. was incorporated in 2011 and is headquartered in marlborough, massachusetts.
Company profile
Ticker
PHIO
Exchange
Website
CEO
Gerrit Dispersyn
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
RXi Pharmaceuticals Corp
SEC CIK
PHIO stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
22 Apr 24
8-K
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
2 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Jan 24
424B3
Prospectus supplement
28 Dec 23
EFFECT
Notice of effectiveness
28 Dec 23
CORRESP
Correspondence with SEC
22 Dec 23
UPLOAD
Letter from SEC
21 Dec 23
S-1
IPO registration
19 Dec 23
D
$5.40 mm in options / securities to be acquired, sold $532.56 k, 4 investors
19 Dec 23
Latest ownership filings
4
Caitlin Kontulis
5 Mar 24
4
Robert J Bitterman
27 Feb 24
4
Robert J Bitterman
22 Feb 24
4
Caitlin Kontulis
20 Feb 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
4
Robert J Bitterman
3 Oct 23
4
Robert J Bitterman
5 Jul 23
4
Robert L Ferrara
15 Jun 23
4
Caitlin Kontulis
3 Mar 23
4
Curtis Lockshin
22 Feb 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.46 mm | 8.46 mm | 8.46 mm | 8.46 mm | 8.46 mm | 8.46 mm |
Cash burn (monthly) | 966.67 k | 506.42 k | 925.33 k | 971.25 k | 966.67 k | 923.67 k |
Cash used (since last report) | 6.65 mm | 3.48 mm | 6.36 mm | 6.68 mm | 6.65 mm | 6.35 mm |
Cash remaining | 1.81 mm | 4.97 mm | 2.09 mm | 1.78 mm | 1.81 mm | 2.10 mm |
Runway (months of cash) | 1.9 | 9.8 | 2.3 | 1.8 | 1.9 | 2.3 |
Institutional ownership, Q2 2023
28.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 14 |
Opened positions | 6 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 726.00 mm |
Total shares | 1.32 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 811.83 k | $0.00 |
CVI Investments | 228.90 k | $616.00 k |
Sabby Management | 156.75 k | $449.88 mm |
Vanguard | 24.38 k | $69.97 mm |
Bridgeway Capital Management | 23.49 k | $67.41 mm |
Anson Funds Management | 22.57 k | $64.78 mm |
Cambridge Investment Research Advisors | 14.23 k | $41.00 k |
Renaissance Technologies | 11.28 k | $32.00 k |
Cetera Investment Advisers | 10.67 k | $30.61 mm |
BMO Bank of Montreal | 10.00 k | $38.50 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Caitlin Kontulis | Common stock, $0.0001 par value | Payment of exercise | Dispose F | No | No | 0.958 | 335 | 320.93 | 10,643 |
26 Feb 24 | Robert J Bitterman | Common stock, $0.0001 par value | Buy | Acquire P | No | No | 0.91 | 2,500 | 2.28 k | 18,990 |
20 Feb 24 | Robert J Bitterman | Common stock, $0.0001 par value | Payment of exercise | Dispose F | No | No | 0.76 | 1,804 | 1.37 k | 16,490 |
17 Feb 24 | Caitlin Kontulis | Common stock, $0.0001 par value | Payment of exercise | Dispose F | No | No | 0 | 523 | 0.00 | 10,978 |
15 Feb 24 | Caitlin Kontulis | Common stock, $0.0001 par value | Payment of exercise | Dispose F | No | No | 0 | 658 | 0.00 | 11,501 |
1 Oct 23 | Robert J Bitterman | Common stock, $0.0001 par value | Payment of exercise | Dispose F | No | No | 1.51 | 917 | 1.38 k | 18,294 |
News
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
23 Apr 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
23 Apr 24
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
23 Apr 24
Why Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday?
22 Apr 24
Phio's Intratumoral Injection Of PH-762 Significantly Inhibits Tumor Growth In Murine Tumor Models And May Generate Memory-Specific T Cells; Injection In Murine Tumors Shows The Compound Is Well Tolerated
22 Apr 24
Press releases
Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
22 Apr 24
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
16 Apr 24
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
11 Apr 24
National Spotlight Features Phio's Innovative RNAi Technology Platform
3 Apr 24
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
2 Apr 24